Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr 14:4:64.
doi: 10.3389/fonc.2014.00064. eCollection 2014.

Targeting PI3K/Akt/mTOR Signaling in Cancer

Camillo Porta  1 , Chiara Paglino  1 , Alessandra Mosca  2
Affiliations
Review

Targeting PI3K/Akt/mTOR Signaling in Cancer

Camillo Porta et al. Front Oncol. .

Abstract

The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.

Keywords: Akt; PI3K; everolimus; inhibitors; mTOR; novel agents; ridaforolimus; temsirolimus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A schematic representation of the PI3K/Akt/mTOR pathway.
Figure 2
Figure 2
Structure of clinically available mTOR inhibitors.
See this image and copyright information in PMC

References

    1. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev (1999) 13:2905–2710.1101/gad.13.22.2905 - DOI - PubMed
    1. Shaw RJ, Cantley LC. Ras, PI3K, and mTOR signalling controls tumor cell growth. Nature (2006) 441:424–3010.1038/nature04869 - DOI - PubMed
    1. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 4:988–100410.1038/nrd1902 - DOI - PubMed
    1. Chen YL, Law PY, Loh HH. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents (2005) 5:575–8910.2174/156801105774574649 - DOI - PubMed
    1. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem (1998) 67:481–50710.1146/annurev.biochem.67.1.481 - DOI - PubMed